Loading...
Loading...
FULC| Name | Value |
|---|---|
| Revenues | 80.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | 79.6M |
| Operating Expense | 27.1M |
| Operating I/L | 52.5M |
| Other Income/Expense | 2.9M |
| Interest Income | 0.0M |
| Pretax | 55.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 55.4M |
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products for genetically defined diseases with high unmet medical needs. Its product candidates include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and other hemoglobinopathies. The company is also discovering drug targets for rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research collaborations with Acceleron Pharma Inc. and a strategic collaboration with MyoKardia, Inc. to develop and commercialize novel targeted therapies for genetic cardiomyopathies.
